Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3

No abstract is available for this paper.

• Publication year

  1995

• Venue

  International Journal of Cancer

• Publication date

  1995-12-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.2910630622PMID 8847150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of MAGE genes in primary and metastatic cutaneous melanoma

  1995cited by this paper
• Tumor antigens recognized by T lymphocytes.

  1994cited by this paper
• Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

  1994cited by this paper
• Expression of mage genes by non‐small‐cell lung carcinomas

  1994cited by this paper
• Spontaneous regression of subcutaneous metastasis of cutaneous melanoma.

  1992cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper

• Shaping Antitumor Immunity with Peptide Vaccines: Implications of Immune Modulation at the Vaccine Site

  2025cites this paper
• Exosome-based cancer vaccine: a cell-free approach

  2025cites this paper
• Therapeutic Vaccination in Lung Cancer: Past Attempts, Current Approaches and Future Promises

  2025cites this paper
• Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a- and Siglece-based vaccination induces anti-tumor immunity and inhibits metastasis

  2023cites this paper
• Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis

  2023cites this paper
• Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen

  2023cites this paper
• Exosome-Based Vaccines: History, Current State, and Clinical Trials

  2021cites this paper
• Breakthrough concepts in immune‐oncology: Cancer vaccines at the bedside

  2020cites this paper
• MHC Class-I Loss and Cancer Immune Escape

  2019cites this paper
• The Clinical Trial Landscape for Melanoma Therapies

  2019cites this paper
• Anticancer Immunotherapy: Prospects and Challenges

  2019cites this paper
• HLA Class-I Expression and Cancer Immunotherapy.

  2019cites this paper
• Immunothérapie : après le focus sur les voies de signalisation, l’activation d’un système

  2017cites this paper
• Melanoma: tumor microenvironment and new treatments

  2017cites this paper
• AutoimmunityResults in Tumor Rejection But Not Activation of Low Avidity CTL Specific for a Self

  2017cites this paper
• Lewis-Sumner syndrome associated with infliximab therapy for psoriasis*

  2017cites this paper
• [Immunotherapy: Activation of a system not a pathway].

  2017cites this paper
• MAGE-A Antigens and Cancer Immunotherapy

  2017cites this paper
• Análise da expressão da proteína NY-ESO-1 no melanoma cutâneo

  2016cites this paper
• Cancer vaccines

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• MAGE-A3: an immunogenic target used in clinical practice.

  2015cites this paper
• Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy

  2014cites this paper
• Evolution of the strategies for screening and identifying human tumor antigens.

  2014cites this paper
• Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer--a feasibility study.

  2014cites this paper
• Identification of Vβ7.1_H3F7 as a therapeutic gene encoding TCR specific to hepatocellular carcinoma.

  2014cites this paper
• Peptide-based vaccines for cancer therapy

  2014cites this paper
• Molecular Basis for Tumor Immunity

  2014cites this paper
• Beta-2-microglobulin gene transfer in hla class i deficient tumor cells using recombinant adenovirus

  2014cites this paper
• Clinical Significance of Immunohistochemical Expression of Cancer/Testis Tumor-associated Antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in Patients with Non-small Cell Lung Cancer

  2014cites this paper
• Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

  2014cites this paper
• Guidance for peptide vaccines for the treatment of cancer

  2014cites this paper
• Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

  2013cites this paper
• Antigensof Autologous Melanoma Glycoprotein 100 and Does Not Alter the Recognition of Melanoma Tumor Antigen Primary Human Lymphocytes Affords Avid High Efficiency TCR Gene Transfer into

  2013cites this paper
• Cancer vaccines

  2013cites this paper
• CHALLENGES AND ACHIEVEMENTS IN INFECTIOUS AND AUTOIMMUNE DISEASES

  2013cites this paper
• Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity

  2013cites this paper
• Immune correlates of melanoma survival in adoptive cell therapy

  2013cites this paper
• Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  2013cites this paper
• Functional Heterogeneity of Vaccine-Induced

  2013cites this paper
• Immunology of lung cancer

  2012cites this paper
• Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.

  2012cites this paper
• Minimalistic immunologically defi ned gene expression T helper cell 1 (MIDGE-Th1 ® ) vectors coding for Inter- leukin 12 and -18 in combination with the transfection agent SAINT-18 have systemic antitumoral effects on equine melanomas

  2012cites this paper
• Prospects for the Therapeutic Use of Anticancer Vaccines

  2012cites this paper
• Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome.

  2012cites this paper
• Can breast cancer stem cells evade the immune system?

  2012cites this paper
• Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment.

  2012cites this paper
• Functional characterization of allorestricted T cell receptors (TCRs) with specificity for HER2/neu and FMNL1 in vitro and in vivo for potential clinical application

  2011cites this paper
• Recombinant protein vaccination for antigen-specific cancer immunotherapy

  2011cites this paper
• Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?

  2011cites this paper
• Principles of the design and use of medical vaccines in oncology

  2011cites this paper
• Labelling dendritic cells with SPIO has implications for their subsequent in vivo migration as assessed with cellular MRI.

  2011cites this paper
• Efficacy of B16OVA Tumour Cell Lysate Conjugated to Rabbit Haemorrhagic Disease Virus Virus-Like Particles as an Anti-Tumour Vaccine

  2011cites this paper
• Therapeutic Cancer Vaccines in Combination with Conventional Therapy

  2010cites this paper
• Oxidative Stress and DNA Methylation in Prostate Cancer

  2010cites this paper
• Circumventing immune tolerance through epigenetic modification.

  2010cites this paper
• Cancer–germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment

  2010cites this paper
• MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

  2010cites this paper
• Frequenzevaluation von Ras- und Influenza-spezifischen T-Zellen bei Pankreaskarzinompatienten

  2009cites this paper
• Gene therapy strategies utilizing carcinoembryonic antigen as a tumor associated antigen for vaccination against solid malignancies

  2009cites this paper
• Chapter 54 – Cancer-Specific Vaccines

  2008cites this paper
• Immune Effector Cells in the Tumor Microenvironment: Their Role in Regulation of Tumor Progression

  2008cites this paper
• New dimensions in vaccinology: A new insight

  2008cites this paper
• Peptide-based tumor vaccines

  2008cites this paper
• Peptide-Based Active Immunotherapy in Cancer

  2008cites this paper
• Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.

  2008cites this paper
• Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

  2008cites this paper
• A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma

  2007cites this paper
• Adjuvante Immuntherapie des felinen Fibrosarkoms mit rekombinantem felinen Interferon-ω

  2007cites this paper
• Adjuvante Immuntherapie des felinen Fibrosarkoms mit rekombinantem felinen Interferon-omega

  2007cites this paper
• GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

  2007cites this paper
• Cancer testis antigens – their importance in immunotherapy and in the early detection of cancer

  2006cites this paper
• Human T cell responses against melanoma.

  2006cites this paper
• Identification of HLA‐A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung

  2006cites this paper
• Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.

  2006cites this paper
• Immunity to melanoma antigens: from self-tolerance to immunotherapy.

  2006cites this paper
• Tumor-Induced Immune Suppression and Immune Escape

  2006cites this paper
• Expression of MAGE tumor-associated antigen in thyroid carcinomas

  2006cites this paper
• Structure-function Analysis of NRAGE : A Protein Involved in Developmental Neural Apoptosis

  2006cites this paper
• A Senior Honors Thesis Presented in Partial Fulfillment of the Requirements for graduation with distinction in Molecular Genetics in the undergraduate colleges of The Ohio State University by

  2006cites this paper
• Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

  2006cites this paper
• Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

  2006cites this paper
• Tumor vaccine: current trends in antigen specific immunotherapy.

  2005cites this paper
• Enhanced Maturation and Functional Capacity of Dendritic Cells Induced by Mannosylated L2 Domain of ErbB2 Receptor

  2005cites this paper
• Adoptive transfer of activated autologous lymphocytes into patients with metastatic lung cancer

  2005cites this paper
• Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

  2005cites this paper
• Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients

  2005cites this paper
• Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions

  2005cites this paper
• Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination

  2005cites this paper
• Effects of Androgen Ablation on Anti-Tumor Immunity

  2005cites this paper
• Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

  2005cites this paper
• TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma

  2005cites this paper
• The expression of MAGE and GAGE genes in uterine cervical carcinoma of Korea by RT-PCR with common primers.

  2005cites this paper
• Identification of Noncanonical Melanoma-Associated T Cell Epitopes for Cancer Immunotherapy1

  2005cites this paper
• Target Antigens for Prostate Cancer Immunotherapy

  2004cites this paper
• T-cell epitope peptide vaccines

  2004cites this paper
• T‐cell receptor Vβ gene usage by T cells reactive with the tumor‐rejection antigen SART‐1 in oral squamous cell carcinoma

  2004cites this paper
• Identification of a MHC class-II restricted epitope in carcinoembryonic antigen

  2004cites this paper
• Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.

  2004cites this paper
• T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.

  2004cites this paper